Monopar Therapeutics Inc. (MNPR) – What Are Brokerages Saying About This Stock?

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have earned an average rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $122.78.

Several equities analysts recently commented on the company. Barclays reissued an “overweight” rating and issued a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. Zacks Research lowered Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Morgan Stanley restated an “overweight” rating and set a $130.00 target price on shares of Monopar Therapeutics in a research note on Monday, August 17th. Finally, HC Wainwright increased their price target on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, Director Christopher M. Starr sold 8,400 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the completion of the transaction, the director owned 5,173 shares in the company, valued at $406,080.50. This represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the transaction, the director directly owned 23,751 shares in the company, valued at approximately $2,654,649.27. The trade was a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 51,920 shares of company stock valued at $4,527,913. Corporate insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new stake in shares of Monopar Therapeutics during the second quarter worth approximately $7,124,000. Walleye Capital LLC purchased a new position in Monopar Therapeutics during the 1st quarter worth $3,458,000. Siren L.L.C. raised its position in Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after acquiring an additional 53,336 shares during the period. Finally, State Street Corp boosted its holdings in shares of Monopar Therapeutics by 24.1% in the third quarter. State Street Corp now owns 229,771 shares of the company’s stock valued at $18,306,000 after acquiring an additional 44,669 shares in the last quarter. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Stock Down 0.1%

NASDAQ:MNPR opened at $71.73 on Thursday. The company has a fifty day simple moving average of $84.40 and a two-hundred day simple moving average of $77.39. The company has a market cap of $481.45 million, a price-to-earnings ratio of -33.06 and a beta of 1.62. Monopar Therapeutics has a 52 week low of $50.07 and a 52 week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.02. On average, analysts expect that Monopar Therapeutics will post -2.98 EPS for the current year.

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.